Investigating early chronic obstructive pulmonary disease in China
A Cohort Study of Early Chronic Obstructive Pulmonary Disease for China Pulmonary Health Study Stage II
This study is trying to understand how early chronic obstructive pulmonary disease (COPD) develops and varies in people, to find better ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 6 sites (Hangzhou, Zhejiang and 5 other locations) |
| Trial ID | NCT05028985 on ClinicalTrials.gov |
What this trial studies
This project aims to explore the progression and heterogeneity of early chronic obstructive pulmonary disease (COPD) using large-scale population cohort databases and biological sample libraries. By employing multi-omics sequencing techniques, the study seeks to establish new standards for COPD stages and subtypes, linking clinical phenotypes with molecular and cellular characteristics. Additionally, animal models will be constructed to investigate pathogenic factors and potential therapeutic targets for early-stage COPD. The ultimate goal is to provide new insights and scientific evidence for the treatment of COPD.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals younger than 50 years with a smoking history of more than 10 pack-years and early airflow limitation.
Not a fit: Patients with cancer, other respiratory diseases, or mental illness may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for early-stage COPD patients.
How similar studies have performed: Other studies have shown success in utilizing multi-omics approaches to understand COPD, indicating that this methodology is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * younger than 50 years * smoking more than 10 pack-years * early airflow limitation(post-bronchodilator FEV1/FVC\< lower limit of normal) Exclusion Criteria: * cancer * other respiratory diseases * mental illness
Where this trial is running
Hangzhou, Zhejiang and 5 other locations
- Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
- Capital Medical University — Beijing, China (Recruiting)
- China-Japan Friendship Hospital — Beijing, China (Recruiting)
- Institue of Basic Medical Sciences Chinese Academy of Medical Sciences — Beijing, China (Recruiting)
- Peking University Third Hospital — Beijing, China (Recruiting)
- Shanghai Ninth People's Hospital, Shanghai JiaoTong university school of medicine — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Ting Yang — China-Japan Friendship Hospital
- Study coordinator: Chen Wang
- Email: cyh-birm@263.net
- Phone: +86 010 69156477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.